Ex vivo culture of stem cells

• US 5,922,597 A
• Filed: 07/14/1997
• Issued: 07/13/1999
• Est. Priority Date: 11/14/1995
• Status: Expired due to Fees

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Miller, Jeffrey S., McGlave, Philip B.
• Primary Examiner(s): Guzo, David
• Application Number:
  US08/860,866
• Time in Patent Office: 729 Days
• Field of Search: 435/172.1, 435/172.3, 435/325, 435/372, 435/372.1, 435/375, 435/377, 435/366, 435/372.2, 435/372.3, 435/383, 435/384, 435/385, 435/386, 435/387
• US Class Current: 435/372.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/21 Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2502/1394 Bone marrow stromal cells; whole marrow
• CPC Class Codes: C12N 5/0646 Natural killers cells [NK], NKT cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

A method for the culture of hematopoietic cells is provided comprising culturing said cells in stromal conditioned medium comprising one or more cytokines selected from the group consisting of MIP-1α, IL-3, SCF, BB10010 and PF-4, so that the ability of the stem cells to self-replicate and differentiate is maintained or the ability of the committed progenitors to expand and differentiate is maintained.

Claims

1. A method for culturing hematopoietic cells, comprising:

culturing a population of human hematopoietic cells comprising stem cells or committed progenitor cells in a stromal conditioned medium in the absence of stromal cells, wherein the medium comprises an effective added amount of one or more cytokines selected from the group consisting of MIP-1α

, IL-3, SCF, BB10010 and PF-4, so that the ability of the stem cells to self-replicate and differentiate is maintained or the ability of the committed progenitors to expand and differentiate is maintained.

2. The method of claim 1 wherein the hematopoietic cells consist essentially of committed progenitor cells.

3. The method of claim 1 wherein the hematopoietic cells comprise stem cells.

4. The method of claim 1 wherein the hematopoietic cells are derived from bone marrow cells.

5. The method of claim 1 wherein the hematopoietic cells are chronic myelogenous leukemia bone marrow cells.

6. The method of claim 1 wherein the hematopoietic cells are derived from peripheral blood or from newborn cord blood.

7. The method of claim 1 wherein the hematopoietic cell population is allogeneic.

8. The method of claim 1 wherein the hematopoietic cell population is autologous.

9. The method of claim 2 wherein the hematopoietic cells consist essentially of natural killer cells.

10. The method of claim 3 wherein the stem cells are CD34⁺.

11. The method of claim 10 wherein the stem cells are Lin^- CD34^+DR-.